SHANGHAI, China — The use of metformin significantly reduced the risk of cardiovascular events among diabetic patients with coronary artery disease when compared with the sulfonylurea glipizide, ...
Glipizide/metformin HCl; 2.5mg/250mg, 2.5mg/500mg, 5mg/500mg; tabs. Adjunct to diet and exercise in type 2 diabetes, as initial therapy or as second-line therapy when response to a sulfonylurea or ...
STOCKHOLM--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced results from a randomized, double-blind Phase 3 clinical study in adults with type 2 ...
ONGLYZA 5 mg plus metformin also resulted in a significantly smaller rise per week in HbA1c from week 24 to week 52 compared to titrated glipizide plus metformin. Overall adverse events excluding ...
Episodes of low blood sugar were less frequent in patients treated with dapagliflozin added to metformin than in patients treated with glipizide added to metformin In addition to sustained reductions ...
Moderate-risk patients with diabetes treated with a sulfonylurea appear to be at a higher risk of major adverse cardiovascular events than those who receive a dipeptidyl peptidase-4 (DPP-4) inhibitor, ...
Please provide your email address to receive an email when new articles are posted on . A second novel variant was linked to reduced glucose response to glipizide, Josephine Li, MD, an endocrinologist ...
Glipizide is an oral drug used to treat type 2 diabetes. It belongs to the sulfonylurea drug class, which also includes glimepiride Amaryl, glyburide Diabeta, Glynase, tolbutamide, and tolazamide. In ...
Investigational Compound Dapagliflozin Added to Metformin Sustained Reductions in Blood Sugar Levels in Adult Patients with Type 2 Diabetes in Two-Year Study Episodes of low blood sugar were less ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback